Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
92.39
-0.52 (-0.55%)
May 9, 2025, 12:47 PM - Market open
Revvity Revenue
Revvity had revenue of $664.76M in the quarter ending March 30, 2025, with 2.28% growth. This brings the company's revenue in the last twelve months to $2.77B, up 1.62% year-over-year. In the year 2024, Revvity had annual revenue of $2.76B with 0.16% growth.
Revenue (ttm)
$2.77B
Revenue Growth
+1.62%
P/S Ratio
4.09
Revenue / Employee
$251,806
Employees
11,000
Market Cap
10.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 2.76B | 4.46M | 0.16% |
Dec 31, 2023 | 2.75B | -561.25M | -16.95% |
Jan 1, 2023 | 3.31B | -515.99M | -13.48% |
Jan 2, 2022 | 3.83B | 1.16B | 43.73% |
Jan 3, 2021 | 2.66B | -220.44M | -7.64% |
Dec 29, 2019 | Pro | Pro | Pro |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RVTY News
- 2 hours ago - Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy - Seeking Alpha
- 9 days ago - Revvity to Present at Upcoming Investor Conferences - Business Wire
- 11 days ago - Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop - Benzinga
- 11 days ago - Revvity beats quarterly estimates on steady demand for medical equipment - Reuters
- 11 days ago - Revvity Announces Financial Results for the First Quarter of 2025 - Business Wire
- 14 days ago - Revvity Board Declares Quarterly Dividend - Business Wire
- 16 days ago - Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation - Business Wire